⚠️ JAN 12 – FEB 6 CYBERATTACK: ALL ORDERS REFUNDED • DO NOT PURCHASE UNTIL FURTHER NOTICE • CONTACT support@anubis.estate FOR REFUND STATUS
ApprovedPharmaceutical

(TO DELIVER) AVOBENZONE 3%, HOMOSALATE 10%, OCTISALATE 5%, OCTOCRYLENE 5%

Formula Pending

Molecular Mass
N/A
CAS Registry
N/A
Risk Class
LOW
Last Audit
Jan 1, 2024

Research Abstract

Pharmaceutical medication

(TO DELIVER) AVOBENZONE 3%, HOMOSALATE 10%, OCTISALATE 5%, OCTOCRYLENE 5% is a pharmaceutical asset inside marketed initiatives, optimized for therapeutic and clinical research.

The dossier currently sits in approved with a low risk rating, meaning it is cleared for baseline monitoring protocols.

Supply records cite CAS N/A with updates logged 2024-01-01.

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Primary Vectors

TherapeuticClinical Research

Nomenclature

(TO DELIVER) AVOBENZONE 3%, HOMOSALATE 10%, OCTISALATE 5%, OCTOCRYLENE 5%

Reference Material

  1. [1] Anubis Compound Registry • CAS N/A
  2. [2] Operations Pulse • Marketed
  3. [3] Risk Governance Ledger • LOW clearance for TO-DELIVER-AVOBENZONE-3-HOMOSALATE-10-OCTISALATE-5-OCTOCRYLENE-5